Table 2.
The antiproliferative activity of Compounds 22–26 and cisplatin as a reference compound.
| Compound | Human Cell Line/IC50 ± SD (µM) | |||
|---|---|---|---|---|
| C-32 | SNB-19 | MDA-MB-231 | HFF-1 | |
| 22 | 158.7 ± 4.6 | 250.4 ± 4.3 | Neg | 260.0 ± 5.6 |
| 23 | 144.6 ± 4.8 | 186.0 ± 5.0 | 22.5 ± 2.4 | 97.6 ± 4.0 |
| 24 | 3.1 ± 0.1 | 2.4 ± 0.1 | 110.2 ± 8.1 | Neg |
| 25 | 115.6 ± 2.9 | 168.7 ± 4.8 | 16.5 ± 1.9 | 27.1 ± 1.1 |
| 26 | 30.3 ± 3.1 | 22.8 ± 1.4 | 2.0 ± 0.2 | 17.5 ± 1.3 |
| 27 | 48.4 ± 8.9 | 31.5 ± 2.5 | 25.1 ± 2.4 | 13.0 ± 3.4 |
| 28 | 155.4 ± 3.7 | 157.1 ± 5.7 | 173.5 ± 5.9 | 27.8 ± 1.2 |
| cisplatin | 16.4 ± 1.2 | 18.9 ± 0.4 | 25.5 ± 0.2 | 9.1 ± 1.8 |
Note: Neg: negative in the concentration used.